By: IPP Bureau
Last updated : August 13, 2025 3:55 pm
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Marksans Pharma Ltd. announced its unaudited financial results for the quarter ended June 30, 2025.
The company reported revenue of Rs. 620 crore, up 5 per cent year-on-year, driven by growth in the US market through new product launches in gastrointestinal, pain management, and digestive health segments.
Gross profit rose 8.9 per cent to Rs. 358.2 crore, with gross margin improving by 209 basis points to 57.8 per cent due to liquidation of higher-cost inventories and lower input costs. EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent, and EPS was Rs.1.3. The company closed the quarter with a strong cash balance of Rs. 711 crore.
Mark Saldanha, Managing Director, said, “While Q1FY26 was a seasonally soft quarter, we delivered year-on-year revenue growth of 5%, while gross profit increased by 8.9%. This was supported by successful new product launches in the US markets and the easing of raw material costs. While EBITDA and net profit margins were impacted by ramp-up costs, a one-time ECL provision for the emerging market division, and forex adjustments, these are transient and do not affect the fundamental momentum of our business.
We are already seeing encouraging early signs of demand recovery in key markets such as the U.S., U.K., and Australia. With the Goa facility integration nearing completion, we are now sharply focused on scaling capacity, enhancing operational efficiency, and unlocking synergies.
Our execution discipline, combined with a robust pipeline and expanding market presence, positions us well to deliver sustainable, long-term value. We remain committed to driving growth, improving returns, and creating enduring value for our stakeholders in FY26 and beyond.”
In the US and North America, revenue was Rs. 327.6 crore, supported by improved demand expected to continue into the second quarter. The UK and Europe business posted Rs. 203.8 crore in revenue, with pricing pressure in some products offset by four new high-margin liquid product launches. The Australia and New Zealand market generated Rs. 57 crore in revenue, with performance impacted by strong prior-quarter sales and some destocking, but signs of recovery are emerging. The Rest of World market reported Rs. 31.6 crore, aided by favorable market conditions and well-timed shipments.
Net cash from operations in the quarter was Rs. 48.7 crore, with capital expenditure of Rs. 37.8 crore. The working capital cycle stood at approximately 159 days, reflecting front-loaded US shipments ahead of expected tariff changes. Research and development expenditure was Rs 12.1 crore, representing 2 per cent of consolidated revenue.